- The rebound was narrow rather than broad. Nasdaq 100 futures rose 1.1% and S and P 500 futures 0.5%, while Dow futures fell 0.2% and the MSCI World Index also declined 0.2%. The recovery was specific to US technology rather than global or market-wide.
- Intel gained 3% after JPMorgan upgraded it to neutral, with the bank noting the turnaround might take years while management execution has been solid. A stock moving 3% on an upgrade to hold indicates how far expectations had fallen, and it followed the chip benchmark’s longest losing streak in 18 years.
- Within the largest technology companies the dispersion was telling. Nvidia rose 1.5% and Amazon 1.4%, while Tesla fell 0.1% and Apple 0.2%, with Meta essentially flat at 0.02% ahead of results. The buying concentrated in AI infrastructure names rather than lifting megacaps generally.
- The largest single move came from biotech. Disc Medicine soared 55% after its investigational drug bitopertin met all primary and secondary endpoints in a Phase 3 trial in adults and adolescents with erythropoietic protoporphyria, a rare blood disorder.
What Happened?
Cleveland-Cliffs rose 10% after third quarter adjusted earnings before interest, tax, depreciation and amortisation beat the average analyst estimate. Silgan gained 1% after announcing, with funds affiliated to American Industrial Partners, an all-cash deal to buy Trivium Packaging. Shares in neoclouds and optical firms also rose amid a broad rally in AI-related names.
Why It Matters?
The composition of this bounce matters more than its size. Nasdaq futures up while Dow futures and the MSCI World Index fall describes money returning to a specific group of stocks rather than risk appetite recovering generally. Within that group the buying went to AI infrastructure, with Nvidia and Amazon leading while Apple and Tesla declined. That is consistent with a technical rebound after the semiconductor index’s longest losing run since 2008 rather than a reassessment of the concerns that caused it, which were about financing, credit spreads and returns on capital rather than about near-term demand. Intel is the clearest sentiment reading available. An upgrade to neutral is a statement that a stock is no longer worth selling, accompanied by a caveat that recovery may take years, and it produced a 3% gain. Positioning had evidently become extremely negative, which is often a precondition for a bounce and tells you nothing about whether the bounce persists. The Disc Medicine result is a genuine clinical event rather than a sentiment move. Meeting all primary and secondary endpoints in a Phase 3 trial is an unambiguous outcome, and in rare disease the regulatory path from there is usually clearer than in larger indications. A 55% move reflects that binary resolution. Cleveland-Cliffs beating on EBITDA is worth noting against the wider steel picture, where European producers are being restructured and sold, with Celsa’s creditor-owners seeking an exit and Silgan consolidating metal packaging.
What Next?
Meta, Tesla and SpaceX report this week, and Bloomberg Intelligence data shows technology drives most of the index’s earnings growth, so those results determine whether this holds. Watch whether the Dow and global indices join the rebound, since their absence marks this as narrow. Credit spreads on AI borrowers remain the better indicator than equity prices, having led the selloff. For Disc Medicine the next step is the regulatory filing pathway following a clean Phase 3 result.
Affected Tickers and Coins: IRON, CLF, INTC, NVDA, AMZN, SLGN, TSLA, AAPL
Source: Bloomberg
